Preclinical evaluation of binimetinib (MEK162) delivered via polymeric nanocarriers in combination with radiation and temozolomide in glioma

BACKGROUND AND PURPOSE: Glioblastoma multiforme (GBM) is the most aggressive subtype of malignant gliomas, with an average survival rate of 15 months after diagnosis. More than 90% of all GBMs have activating mutations in the MAPK/ERK pathway. Recently, we showed the allosteric MEK1/2 inhibitor bini...

Descripción completa

Detalles Bibliográficos
Autores principales: Bikhezar, Fatima, de Kruijff, Robin M., van der Meer, Astrid J. G. M., Torrelo Villa, Guzman, van der Pol, Susanne M. A., Becerril Aragon, Gabriel, Gasol Garcia, Ana, Narayan, Ravi S., de Vries, Helga E., Slotman, Ben J., Denkova, Antonia G., Sminia, Peter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2019
Materias:
Laboratory Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6971148/
https://www.ncbi.nlm.nih.gov/pubmed/31875307
http://dx.doi.org/10.1007/s11060-019-03365-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6971148/
https://www.ncbi.nlm.nih.gov/pubmed/31875307
http://dx.doi.org/10.1007/s11060-019-03365-y

Ejemplares similares